© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
May 15, 2013
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy.